SAT304 Improved Biochemical Control With Dose Reduction In Chronic Glucocorticoid Therapy: A Phase III Extension Study Of Chronocort (Efmody) In The Treatment Of Congenital Adrenal Hyperplasia (CAH)

Disclosure: R.J. Ross: Employee; Self; Diurnal, A Neurocrine Biosciences Company. D.P. Merke: None. A. Mallappa: None. W. Arlt: None. A. Brac de la Perriere: None. A.L. Hirschberg: None. A. Juul: None. J.D. Newell-Price: None. C.G. Perry: None. A. Prete: None. A. Rees: None. N. Reisch: None. M. Stik...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Richard John M, Merke, Deborah P, Mallappa, Ashwini, Arlt, Wiebke, de la Perriere, Aude Brac, Hirschberg, Angelica Linden, Juul, Anders, Newell-Price, John D C, Perry, Colin Graham, Prete, Alessandro, Rees, Aled, Reisch, Nicole, Stikkelbroeck, Monica, Touraine, Philippe A, Aslam, Naila, Coope, Helen, Porter, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adrenal (Excluding Mineralocorticoids)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557021/
http://dx.doi.org/10.1210/jendso/bvad114.308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557021/
http://dx.doi.org/10.1210/jendso/bvad114.308

Ejemplares similares